In this module, John L. Marshall, MD, reviews practice-changing immunotherapy options for patients with metastatic colorectal cancer, as well as biomarkers that predict response to immune checkpoint inhibitors and the latest data supporting their use in GI malignancies.
In this downloadable slideset, John L. Marshall, MD, reviews the latest clinical data on biomarkers of response to immune checkpoint inhibitors in CRC. These slides accompany the CME-certified Clinical Focus module comprising Dr. Marshall’s expert in-depth discussion.
In this interactive, CME-certified module, Dipen Maru, MD, provides his perspective on how to leverage biomarkers of response to immune checkpoint inhibitors to optimize the care of patients with colorectal cancer.
In this downloadable slideset, Dipen Maru, MD, reviews the latest pathology data on biomarkers of response to immune checkpoint inhibitors in CRC. These slides accompany the CME-certified Clinical Focus module comprising Dr. Maru’s expert in-depth discussion.
In this downloadable resource, expert faculty John L. Marshall, MD, reviews key testing methods for microsatellite instability, PD-L1, and other biomarkers of response to immune checkpoint inhibitors in patients with colorectal cancer. For additional in-depth analysis, please review the accompanying CME-certified text modules, downloadable slides, and ClinicalThought commentaries for expert guidance on the optimal use of immunotherapy in colorectal cancer.
In this video module, watch our distinguished faculty discuss how oncologists and pathologists can leverage established and emerging biomarkers to guide immunotherapy selection in advanced colorectal cancer.
Using MSI and MMR testing to inform treatment decisions with immune checkpoint inhibitors is improving outcomes in colorectal cancer, but many questions remain. Read our thoughts on how these tools are improving clinical practice.
How can immune checkpoint inhibitors improve outcomes in patients with high-risk, progressive colorectal cancer? Read my thoughts on how I incorporate these agents into my practice.
With the first immunotherapy agent approved for use in colorectal cancer, how is this going to change your practice?
Should we evaluate microsatellite status in all patients with colorectal cancer, regardless of stage and treatment experience? Read my thoughts on how I approach testing in my practice.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.